Cellectis acquires assets from Cyto Pulse Sciences Inc.
“Cyto Pulse’s assets are a great strategic fit for Cellectis,” said André Choulika, Chief Executive Officer of Cellectis. “As we announced last year, part of our development strategy is to acquire businesses that complement our existing meganuclease platform and that can be leveraged across all aspects of our business, from research to therapeutics. We saw such an opportunity in the technologies at Cyto Pulse Sciences Inc. and look forward to unlocking the value of these assets.”
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.